UNSPSC 51363504: Butabarbital/phenobarbital/secobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.

UNSPSC 51363504 Butabarbital/phenobarbital/secobarbital is a Commodity code under which state and local governments procure controlled pharmaceutical substances and related drug-management systems to support public health and emergency response initiatives. Recent solicitations reveal that buyers under this code are acquiring naloxone and drug deactivation systems for community health programs, as well as generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that serve state agencies and local government facilities. Procurement approaches range from competitive sealed bidding for specific quantities to request-for-information phases that precede formal requests for proposal for broader pharmaceutical supply agreements.

Activity concentrates in Florida and Minnesota, with Texas's Health and Human Services Commission conducting preliminary market research into direct-to-manufacturer prescription models. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its Community Health Building, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; the RFP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and emphasizes price competitiveness weighted at 75 percent of evaluation criteria. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program before issuing a formal RFP.